Clinical Trials Browser

Terminated × NETWORK × Gemcitabine × Clear all

NCT04871529 2024-12-30

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Phase 2 Terminated

6 enrolled 12 charts

Urinary Bladder Neoplasms

NCT00658593 2023-08-04

Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer

Phase 3 Terminated

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

NCT02718482 2019-05-13

OsteoREC2015

Phase 2 Terminated

Osteosarcoma

NCT01921751 2018-07-13

High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Phase 2 Terminated

20 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00022633 2016-08-11

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

Phase 2 Terminated

65 enrolled 14 charts

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00003378 2013-07-09

Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer

Phase 1 Terminated

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00003316 2013-04-11

Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus

Phase 2 Terminated

Sarcoma

NCT00006224 2013-04-11

Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Phase 2 Terminated

Uterine Cervical Neoplasms

NCT00006482 2013-04-11

Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix

Phase 2 Terminated

Uterine Cervical Neoplasms